Q4 EARNINGS: Danaher in line, but Philips’ dismal run continues
This article was originally published in Clinica
Danaher’s fourth-quarter sales of $5.42bn and adjusted earnings of $1.04 per share came in just ahead of analyst consensus of $5.39bn and $1.03 per share, respectively. Q4 sales were up 3% year-on-year, while core revenues increased 4%; this beat consensus analyst prediction of 2.8% growth and the best result since Q4 2011, according to Jefferies analyst Brandon Couillard. “The upside came from better T&M [test & measurement], environmental and industrial trends,” he added.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.